387 related articles for article (PubMed ID: 32068962)
1. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
2. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
5. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
[TBL] [Abstract][Full Text] [Related]
6. Five-year survival rate analysis: the combination of fortnightly-administration of endostar and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer.
Ma H; Peng F; Xu Y; Bao Y; Hu X; Wang J; Fang M; Kong Y; Dong B; Chen M
Ann Palliat Med; 2021 Jul; 10(7):7560-7570. PubMed ID: 34353044
[TBL] [Abstract][Full Text] [Related]
7. Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
Yuan M; Zhai Y; Men Y; Wang J; Deng L; Wang W; Bao Y; Yang X; Sun S; Ma Z; Liu Y; Wang J; Zhu H; Hui Z
Thorac Cancer; 2021 Dec; 12(23):3208-3215. PubMed ID: 34676669
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.
Bao Y; Peng F; Zhou QC; Yu ZH; Li JC; Cheng ZB; Chen L; Hu X; Chen YY; Wang J; Wang Y; Ma HL; Xu ZM; Lu RB; Deng XW; Chen M
Radiother Oncol; 2015 Feb; 114(2):161-6. PubMed ID: 25497558
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
[TBL] [Abstract][Full Text] [Related]
11. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland.
Zhu Q; Zang Q; Jiang ZM; Wang W; Cao M; Su GZ; Zhen TC; Zhang XT; Sun NB; Zhao C
Asian Pac J Cancer Prev; 2015; 16(9):4013-8. PubMed ID: 25987078
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
Niho S; Yoshida T; Akimoto T; Sakamaki K; Ono A; Seto T; Nishio M; Yamamoto N; Hida T; Okamoto H; Kurata T; Satouchi M; Goto K; Yamanaka T; Ohe Y
Lung Cancer; 2020 Mar; 141():64-71. PubMed ID: 31955002
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
Bi N; Liu L; Liang J; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang J; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Zhang T; Yin W; Li J; He J; Wang L
BMC Cancer; 2020 Apr; 20(1):278. PubMed ID: 32252680
[TBL] [Abstract][Full Text] [Related]
17. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
[TBL] [Abstract][Full Text] [Related]
20. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]